WEKO3
アイテム
{"_buckets": {"deposit": "7652e4a8-1b3e-4dc7-b771-714be4d39859"}, "_deposit": {"created_by": 1, "id": "72996", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "72996"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00072996", "sets": ["28"]}, "author_link": ["719328", "719327", "719332", "719338", "719326", "719334", "719329", "719330", "719336", "719331", "719335", "719333", "719337"], "item_10005_date_7": {"attribute_name": "発表年月日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2018-10-13", "subitem_date_issued_type": "Issued"}]}, "item_10005_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Purpose: Tissue Factor (TF) is a transmembrane protein and its overexpression is associated with increased tumor growth, tumor angiogenesis and metastatic potential in many malignancies, including pancreatic cancer. Near infrared photoimmunotherapy (NIR-PIT) is a new target-cell-specific cancer treatment that enables highly selective cell death after systemic administration of a photosensitizer-antibody conjugate followed by subsequent NIR light exposure. In this study, we describe the photoimmunotherapeutic effect induced by a rat IgG2b anti-TF monoclonal antibody (anti-TF mAb), conjugated to the photosensitizer, Indocyanine green (ICG), in a TF-expressing BxPC-3 pancreatic cancer model. Materials and methods: Specific binding of the anti-TF-ICG antibody to the TF-expressing BxPC-3 pancreatic cancer cell line was examined by fluorescence microscopy. NIR-PIT-induced cell death was determined by using cell viability imaging assay after exposure of the cells to NIR light. Anti-TF-ICG antibody accumulation in xenograft tumor was acquired in in vivo longitudinal fluorescence imaging. To conduct NIR-PIT, tumor-bearing mice were separated into 5 groups: (1) 100 μg of anti- TF-ICG i.v. administration followed by NIR light exposure (50 J/cm2) for two consecutive days (Day 1 and 2); (2) NIR light exposure (50 J/cm2) only for two consecutive days (Day 1 and 2); (3) 100 μg of anti-TF-ICG i.v. administration; (4) 100 μg of unlabeled anti-TF i.v. administration; (5) the untreated control. Biweekly tumor volume measurements, histopathological and immunohistochemical (IHC) analyses of tumors at 3 days post-administration of anti-TF-ICG antibody were performed to monitor the effect of treatments. Results: Dead cells were obviously seen with cell viability imaging assay. Tumor growth was significantly inhibited by NIR-PIT compared with the other control groups (P \u003c 0.01) for 27 days. Tumors received NIR-PIT showed the evidence of necrotic cell death associated features on H\u0026E staining and decreased cell proliferation marker Ki-67-positive cells on IHC examination. Conclusion: The anti-TF-ICG antibody is suitable as a photosensitizer-antibody conjugate for NIR-PIT. Furthermore, NIR-PIT with the anti-TF-ICG antibody conjugate promises to open a new avenue for treatment of TF-expressing pancreatic cancer and that could be ultimately applicable in clinical use.", "subitem_description_type": "Abstract"}]}, "item_10005_description_6": {"attribute_name": "会議概要(会議名, 開催地, 会期, 主催者等)", "attribute_value_mlt": [{"subitem_description": " Annual Congress of the European Association of Nuclear Medicine 2018", "subitem_description_type": "Other"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "U, Winn Aung"}], "nameIdentifiers": [{"nameIdentifier": "719326", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "719327", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sugyo, Aya"}], "nameIdentifiers": [{"nameIdentifier": "719328", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sudo, Hitomi"}], "nameIdentifiers": [{"nameIdentifier": "719329", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takashima, Hiroki"}], "nameIdentifiers": [{"nameIdentifier": "719330", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasunaga, Masahiro"}], "nameIdentifiers": [{"nameIdentifier": "719331", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumura, Yasuhiro"}], "nameIdentifiers": [{"nameIdentifier": "719332", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Tatsuya"}], "nameIdentifiers": [{"nameIdentifier": "719333", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "U Winn Aung", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "719334", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 厚至", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "719335", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "須尭 綾", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "719336", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "須藤 仁美", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "719337", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東 達也", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "719338", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "conference object", "resourceuri": "http://purl.org/coar/resource_type/c_c94f"}]}, "item_title": "Near-infrared Photoimmunotherapy Targeting Pancreatic Cancer With Tissue Factor Antibody", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Near-infrared Photoimmunotherapy Targeting Pancreatic Cancer With Tissue Factor Antibody"}]}, "item_type_id": "10005", "owner": "1", "path": ["28"], "permalink_uri": "https://repo.qst.go.jp/records/72996", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-11-08"}, "publish_date": "2018-11-08", "publish_status": "0", "recid": "72996", "relation": {}, "relation_version_is_last": true, "title": ["Near-infrared Photoimmunotherapy Targeting Pancreatic Cancer With Tissue Factor Antibody"], "weko_shared_id": -1}
Near-infrared Photoimmunotherapy Targeting Pancreatic Cancer With Tissue Factor Antibody
https://repo.qst.go.jp/records/72996
https://repo.qst.go.jp/records/72996527784ba-32a1-40fc-bbf8-334b020a52bf
Item type | 会議発表用資料 / Presentation(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-11-08 | |||||
タイトル | ||||||
タイトル | Near-infrared Photoimmunotherapy Targeting Pancreatic Cancer With Tissue Factor Antibody | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
資源タイプ | conference object | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
U, Winn Aung
× U, Winn Aung× Tsuji, Atsushi× Sugyo, Aya× Sudo, Hitomi× Takashima, Hiroki× Yasunaga, Masahiro× Matsumura, Yasuhiro× Higashi, Tatsuya× U Winn Aung× 辻 厚至× 須尭 綾× 須藤 仁美× 東 達也 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Purpose: Tissue Factor (TF) is a transmembrane protein and its overexpression is associated with increased tumor growth, tumor angiogenesis and metastatic potential in many malignancies, including pancreatic cancer. Near infrared photoimmunotherapy (NIR-PIT) is a new target-cell-specific cancer treatment that enables highly selective cell death after systemic administration of a photosensitizer-antibody conjugate followed by subsequent NIR light exposure. In this study, we describe the photoimmunotherapeutic effect induced by a rat IgG2b anti-TF monoclonal antibody (anti-TF mAb), conjugated to the photosensitizer, Indocyanine green (ICG), in a TF-expressing BxPC-3 pancreatic cancer model. Materials and methods: Specific binding of the anti-TF-ICG antibody to the TF-expressing BxPC-3 pancreatic cancer cell line was examined by fluorescence microscopy. NIR-PIT-induced cell death was determined by using cell viability imaging assay after exposure of the cells to NIR light. Anti-TF-ICG antibody accumulation in xenograft tumor was acquired in in vivo longitudinal fluorescence imaging. To conduct NIR-PIT, tumor-bearing mice were separated into 5 groups: (1) 100 μg of anti- TF-ICG i.v. administration followed by NIR light exposure (50 J/cm2) for two consecutive days (Day 1 and 2); (2) NIR light exposure (50 J/cm2) only for two consecutive days (Day 1 and 2); (3) 100 μg of anti-TF-ICG i.v. administration; (4) 100 μg of unlabeled anti-TF i.v. administration; (5) the untreated control. Biweekly tumor volume measurements, histopathological and immunohistochemical (IHC) analyses of tumors at 3 days post-administration of anti-TF-ICG antibody were performed to monitor the effect of treatments. Results: Dead cells were obviously seen with cell viability imaging assay. Tumor growth was significantly inhibited by NIR-PIT compared with the other control groups (P < 0.01) for 27 days. Tumors received NIR-PIT showed the evidence of necrotic cell death associated features on H&E staining and decreased cell proliferation marker Ki-67-positive cells on IHC examination. Conclusion: The anti-TF-ICG antibody is suitable as a photosensitizer-antibody conjugate for NIR-PIT. Furthermore, NIR-PIT with the anti-TF-ICG antibody conjugate promises to open a new avenue for treatment of TF-expressing pancreatic cancer and that could be ultimately applicable in clinical use. | |||||
会議概要(会議名, 開催地, 会期, 主催者等) | ||||||
内容記述タイプ | Other | |||||
内容記述 | Annual Congress of the European Association of Nuclear Medicine 2018 | |||||
発表年月日 | ||||||
日付 | 2018-10-13 | |||||
日付タイプ | Issued |